Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02187094 · ClinicalTrials.gov registry record · Phase 1
Study Evaluating the Effect of TC-6499 on Gastric Emptying Time in Diabetic Subjects With Gastroparesis
A Phase 1 study, sponsored by Targacept.
- Completed
- Registry status
- Phase 1
- Development phase
- 80
- Enrollment target
NCT02187094 is a Phase 1 study that has completed, run by Targacept. The registered enrollment target is 80 participants.
The verdict
NCT02187094, a Phase 1 study, has completed, sponsored by Targacept.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 80 participants
- Enrollment target
Study Summary
Gastroparesis, also referred to as delayed gastric emptying, is a debilitating, chronic disorder that slows or stops the passage of food from the stomach to the small intestine. The purpose of this study is to test whether TC-6499 is safe and effective at reducing gastric emptying time in diabetic subjects with gastroparesis.
Interventions
- DRUG Placebo
- DRUG TC-6499
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2014-06 |
| Est. Completion | 2015-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02187094
The ClinicalTrials.gov registry entry for NCT02187094 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Targacept, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02187094 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02187094 about?
NCT02187094 is a clinical study titled "Study Evaluating the Effect of TC-6499 on Gastric Emptying Time in Diabetic Subjects With Gastroparesis". Gastroparesis, also referred to as delayed gastric emptying, is a debilitating, chronic disorder that slows or stops the passage of food from the stomach to the small intestine. The purpose of this study is to test whether TC-6499 is safe and effective at reducing gastric emptying time in diabetic s...
What is the current status of trial NCT02187094?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2014-06. Estimated completion is 2015-01.
What interventions are being tested in trial NCT02187094?
The interventions under investigation include: Placebo (DRUG), TC-6499 (DRUG).
Who is sponsoring clinical trial NCT02187094?
This trial is sponsored by Targacept, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.